Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol by Kelly, A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/190523
 
 
 
Please be advised that this information was generated on 2018-05-01 and may be subject to
change.
STUDY PROTOCOL Open Access
Outcome Measures in Rheumatology -
Interventions for medication Adherence
(OMERACT-Adherence) Core Domain Set for
Trials of Interventions for Medication
Adherence in Rheumatology: 5 Phase Study
Protocol
Ayano Kelly1,2,3,4* , Allison Tong4,5, Kathleen Tymms1,2,3, Lyn March6,7,8, Jonathan C. Craig4,5, Mary De Vera9,10,
Vicki Evans11, Geraldine Hassett12,13, Karine Toupin-April14,15, Bart van den Bemt16,17, Armando Teixeira-Pinto4,5,
Rieke Alten18, Susan J. Bartlett19,20, Willemina Campbell21, Therese Dawson22,23, Michael Gill24, Renske Hebing25,
Alexa Meara26, Robby Nieuwlaat27, Yomei Shaw28, Jasvinder A. Singh29,30,31, Maria Suarez-Almazor32,
Daniel Sumpton4,5,33, Peter Wong34,35, Robin Christensen36, Dorcas Beaton37,38,39, Maarten de Wit40,
Peter Tugwell41 and On behalf of the OMERACT-Adherence Group
Abstract
Background: Over the last 20 years, there have been marked improvements in the availability of effective
medications for rheumatic conditions such as gout, osteoporosis and rheumatoid arthritis (RA), which have led to a
reduction in disease flares and the risk of re-fracture in osteoporosis, and the slowing of disease progression in RA.
However, medication adherence remains suboptimal, as treatment regimens can be complex and difficult to
continue long term. Many trials have been conducted to improve adherence to medication. Core domains, which
are the outcomes of most relevance to patients and clinicians, are a pivotal component of any trial. These core
domains should be measured consistently, so that all relevant trials can be combined in systematic reviews and
meta-analyses to reach conclusions that are more valid. Failure to do this severely limits the potential for trial-based
evidence to inform decisions on how to support medication adherence. The Outcome Measures in Rheumatology
(OMERACT) – Interventions for Medication Adherence study by the OMERACT-Adherence Group aims to develop a
core domain set for interventions that aim to support medication adherence in rheumatology.
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Methods/design: This OMERACT-Adherence study has five phases: (1) a systematic review to identify outcome
domains that have been reported in interventions focused on supporting medication adherence in
rheumatology; (2) semi-structured stakeholder interviews with patients and caregivers to determine their views
on the core domains; (3) focus groups using the nominal group technique with patients and caregivers to
identify and rank domains that are relevant to them, including the reasons for their choices; (4) an
international three-round modified Delphi survey involving patients with diverse rheumatic conditions,
caregivers, health professionals, researchers and other stakeholders to develop a preliminary core domain set;
and (5) a stakeholder workshop with OMERACT members to review, vote on and reach a consensus on the
core domain set for interventions to support medication adherence in rheumatology.
Discussion: Establishing a core domain set to be reported in all intervention studies undertaken to support
patients with medication adherence will enhance the relevance and the impact of these results and improve
the lives of people with rheumatic conditions.
Keywords: Core domain set, Outcomes research, Patient-centred outcomes, Clinical trials, Rheumatology,
Medication Adherence, Adherence, Compliance, Persistence
Background
Musculoskeletal conditions are a major cause of dis-
ability worldwide and a burden on individuals and
health-care systems [1]. Advances in drug development
throughout the 21st century have led to a dramatic im-
provement in outcomes for patients with rheumatic
conditions [2, 3]. Conditions such as gout, osteoporosis
and rheumatoid arthritis (RA) are amongst the most
common rheumatic conditions that require long-term
use of medications to improve morbidity, mortality
and other health outcomes [4–7]. However, rates of
medication adherence have been reported to be as low
as 10% in gout, 30% in RA and 45% in osteoporosis
[8–10]. Barriers to medication adherence include per-
ceptual barriers (e.g. concerns about side effects and
uncertainty regarding the efficacy of medications) and
practical barriers (e.g. forgetfulness, inconvenience and
cost) [11–14].
Researchers most commonly support the use of the
word ‘adherence’ in preference to ‘compliance’ or
‘concordance’ [15, 16]. ‘Adherence’ highlights the out-
comes of a shared decision-making approach where
the patient and physician agree upon a treatment plan
that the patient will follow [17]. ‘Compliance’ may
portray a negative paternalistic relationship between
the health-care provider and the patient [15]. ‘Con-
cordance’ emphasises a balanced therapeutic alliance
between the patient and the health-care provider [18];
however, even when ‘concordance’ is successful, pa-
tients may alter or decide not to take their medicine
[18]. Thus, ‘adherence’ remains the preferred term.
While non-pharmacological management is an im-
portant aspect of many rheumatic conditions, adher-
ence to non-pharmacological management is currently
beyond the scope of this study.
The ABC taxonomy of adherence [15, 19] defines ad-
herence as ‘the process by which patients take their
medications as prescribed’ and comprises: (a) initiation
(when the patient takes the first dose of a prescribed
medication), (b) implementation (the extent to which a
patient’s actual dosing corresponds to the prescribed
dosing regimen, from initiation until the last dose) and
(c) persistence (the length of time between initiation and
the last dose, which immediately precedes discontinu-
ation, i.e., when the patient stops taking the prescribed
medication) [15]. The behaviour change wheel will be
used to categorise intervention approaches relevant to
improving adherence behaviours (Appendix 1) [19]. In
the OMERACT-Adherence study, interventions may
focus on any adherence phase (initiation, implementa-
tion or persistence), source of medication, adherence be-
haviour (capability, opportunity or motivation) and
method (education, persuasion, incentivisation, coercion,
training, restriction, environmental restructuring, model-
ling and enablement) (Fig. 1).
Adherence research plays an important role in bridg-
ing the chasm between recommended and best practice
approaches to disease management to improve medica-
tion adherence. Clinical trials have been conducted in
people with rheumatic conditions to resolve ambivalence
and improve medication acceptance and adherence, and
thereby enhance health outcomes [20]. Yet few interven-
tions have demonstrated meaningful improvements in
either medication adherence or clinical outcomes across
medical specialties [20, 21]. A limitation in collating the
results of these trials to identify successful interventions
better is the lack of clarity of core outcomes and the
wide variability in adherence measures. There is need
for a consensus-based core domain set for interventions
to improve medication adherence.
Kelly et al. Trials  (2018) 19:204 Page 2 of 13
Worldwide, there have been many initiatives to de-
velop core domain sets [22, 23], defined as the mini-
mum set of outcome domains that should be
measured and reported in clinical trials for a specific
condition. The Outcome Measures in Rheumatology
(OMERACT) initiative commenced in 1992 and has
expanded to develop core domain sets in multiple
rheumatic conditions [24]. There are now over 20
groups developing core domain sets for specific
conditions [22, 25] and there are several methodo-
logical groups examining the core domains of inter-
ventions and measurements of outcomes that are
relevant across rheumatic conditions, including health
literacy, shared decision-making and work productiv-
ity [26–28].
The OMERACT-Adherence Group aims to establish a
core domain set for clinical trials to support medication
adherence in patients with rheumatic conditions of all
ages (Fig. 2). The OMERACT-Adherence Group was
established in December 2016, and comprises over 40
members from 11 countries: Australia, Canada,
Germany, Greece, the Netherlands, Singapore, the
United Kingdom, Oman, Switzerland, Denmark and the
United States. The members include patients, rheuma-
tologists, nurses, pharmacists, behavioural scientists,
occupational therapists, industry representatives, re-
searchers in outcomes and medication adherence, and
clinical trialists. The patient perspective is highly valued
and integrated into all OMERACT activities, as the ul-
timate aim is to improve clinical outcomes for patients
[29]. Patient research partners are members of the
steering committee of the OMERACT-Adherence
Group and help with the design, conduct, analysis and
dissemination of all studies.
The five specific objectives of this OMERACT-
Adherence study are to: (1) conduct a systematic lit-
erature review to describe the scope and consistency
of domains used in rheumatology interventions ad-
dressing medication adherence; (2) identify additional
domains that are important to patients and their
caregivers and elucidate the reasons for their choices;
(3) ascertain the perspectives of other stakeholders in-
cluding health professionals, researchers, purchasers,
payers, policymakers and industry representatives on
core domains; (4) develop a preliminary core domain
set for clinical trials with input from all stakeholder
groups and (5) seek a consensus on the OMERACT-
Adherence core domain set by a ballot of the OMER-
ACT members.
Methods/design
The OMERACT-Adherence study methodology is adapted
from the OMERACT framework, which is recognised as a
valid approach for establishing a core domain set [22]. The
protocol includes a SPIRIT checklist for recommended
items to address in a clinical trial protocol and related
documents (Additional file 1). The proposed scope of work
to achieve the five OMERACT-Adherence study objectives
is outlined in Fig. 3.
Fig. 1 Scope and definitions of OMERACT-Adherence study
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Phase 1: systematic review of outcome domains and
measures reported in trials of medication adherence
A systematic review will be conducted to identify and
compare outcome domains and measures reported in in-
terventions to improve medication adherence in
rheumatology clinical trials. Outcome domains are the
name of the broad concept that is measured (e.g. adher-
ence, medication knowledge and medication skill). An
outcome is the specific result in a domain arising from
exposure to a causal factor or a health intervention (e.g.
disease-modifying anti-rheumatic drug knowledge in RA
and self-injection skill). An outcome measure includes
the specific measurement instrument (the tool to meas-
ure a quality or quantity of a variable, e.g. pill count),
the specific metric (e.g. a change from baseline) and the
method of aggregation (e.g. mean or median for con-
tinuous measures or proportion for categorical mea-
sures) [30, 31].
Fig. 2 Conceptual schema of OMERACT-Adherence core domain set. ACR American College of Rheumatology
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Search strategy
Electronic databases (MEDLINE, Embase, PsycINFO,
CINAHL and CENTRAL) will be searched to 31 October
2017 to identify all trials of interventions aiming to
improve medication adherence involving patients with
rheumatic conditions. The search will use medical
subject headings for concepts including ‘patient com-
pliance’, ‘medication adherence’, ‘intervention’, ‘inflam-
matory arthritis’, ‘rheumatoid arthritis’, ‘psoriatic
arthritis’, ‘ankylosing spondylitis’, ‘juvenile idiopathic
arthritis’, ‘connective tissue diseases’, ‘systemic lupus
erythematosus’, ‘vasculitis’, ‘Sjogren’s syndrome’, ‘osteo-
porosis’ and ‘gout’ and keywords for concepts that do
not match. The bibliographies of included articles will
be searched by hand.
Types of studies and interventions
All publications studying interventions aiming to im-
prove medication adherence in rheumatic conditions will
be included. Given the limited number of randomised
controlled trials (RCTs) for medication adherence in
rheumatic conditions [20], non-controlled and single-
arm interventions for medication adherence in rheum-
atic conditions will be included.
Types of participants
Studies involving participants of all ages with any
rheumatic condition, including inflammatory arthritis,
connective tissue diseases and osteoporosis, will be
included.
Exclusion criteria
Conference reports and abstracts will be excluded given
their space constraints. For feasibility, the search will be
restricted to English language articles.
Eligibility of studies
Two reviewers will independently screen the abstracts
and full text of all potentially relevant studies. Any
uncertainties on the eligibility of studies to be included
will be resolved through a third reviewer.
Data extraction
Data will be extracted and entered into Microsoft
Excel using a pre-designed form, piloted before full
data extraction with a sample of included studies.
The primary reviewer will extract the following from
all included interventions: first author, date of publi-
cation, countries in which the trial was conducted,
sample size, participant characteristics (age, gender,
condition and medication) and trial duration. In
addition, the type of intervention and all adherence-
related outcomes reported in the trial will be ex-
tracted. Adherence-related outcomes include adher-
ence, and any other outcomes related to adherence
behaviour (including capability, opportunity and mo-
tivation) [19]. For each outcome, the definitions, out-
come measures used, time points, metric and method
of aggregation will be extracted. Clinical outcomes for
specific conditions will not be extracted, as this work
is already being undertaken by other OMERACT
groups [24]. Clinical outcomes are defined as any out-
come that would fall under the four core areas in the
OMERACT filter of death, life impact, resource use
and pathophysiological manifestations for the specific
condition, and they also include adverse events [24].
Data analysis and presentation
Two reviewers will group similar outcomes into out-
come domains, which will be reviewed and modified by
the OMERACT-Adherence steering committee. The fre-
quency of each domain and outcome measure reported
across trials will be calculated. Domains and measures
will be compared with those identified in the 2014
Cochrane Systematic Review of RCTs to enhance medi-
cation adherence, which includes 182 RCTs across other
specialties [32].
Phase 2: stakeholder interviews
Semi-structured interviews will be conducted with pa-
tients and caregivers to ascertain individual perspec-
tives on outcome domains. The interview guide will
incorporate findings from phase 1 and help to give a
greater understanding of the values and beliefs that
underlie candidate domains. Additional outcome do-
mains will also be identified in this phase. We will
follow the consolidated criteria for reporting qualita-
tive research (COREQ) to guide our methods and
reporting [33].
Fig. 3 OMERACT-Adherence study process
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Participants and recruitment
Adults with gout, osteoporosis or RA and their care-
givers (defined by the patient as a significant person or
family member who is aware of the patient’s illness and
treatments) will be eligible to participate in an interview.
Three conditions have been chosen for the phase 2
interviews and phase 3 focus groups, based on feasibility.
They represent common rheumatic conditions with
known poor levels of adherence [8–10]. Patients with
diverse rheumatic conditions will be included in phases
1, 4 and 5 to ensure the core domain set is applicable to
all rheumatic conditions. Participants will be identified
by treating rheumatologists at participating centres in
Australia: Liverpool Hospital (NSW), Canberra Rheuma-
tology (ACT and NSW), BJC Health (NSW) and Royal
North Shore Hospital (NSW). Although this phase in-
cludes participants from one country only, all other
phases will include participants from different countries.
A purposive sampling technique will be applied to in-
clude a broad range of demographic characteristics (age,
gender, socioeconomic status, educational level and eth-
nicity) and clinical characteristics (type, duration and se-
verity of condition).
Based on our experience with previous qualitative
interview studies, target recruitment will be approxi-
mately 30 participants. However, final numbers will be
determined by data saturation, defined as the point at
which no new concepts or outcome domains are being
identified. To achieve adequate participant enrolment at
each site, additional recruiting clinicians will be con-
tacted if needed. Written informed consent will be ob-
tained from all participants.
Data collection
The interviews will be conducted face-to-face as first
preference or by Skype or Facetime or telephone inter-
views if preferred by the participant. Each interview will
take approximately 40 min and will be audio-recorded
and transcribed verbatim. A preliminary interview guide
is provided (Appendix 2).
Data analysis
Transcripts will be available for participants to review
and revise. A summary of the interview findings will
be sent to participants for member checking. The
transcripts will be imported into software HyperRE-
SEARCH (ResearchWare Inc, http://www.researchwar-
e.com, version 3.7.5) for the qualitative data analysis.
Two experienced qualitative investigators will
supervise the coding and development of descriptive
and analytical themes. Using inductive thematic ana-
lysis, the findings from the study will be grounded in
the participant data [34]. The transcripts will be
coded line by line to identify concepts. Similar con-
cepts will be grouped into themes that reflect differ-
ent outcome domains with the reasons for identifying
them. The analysis will be iterative, repetitively mov-
ing between the transcripts, analysis and subsequent
interviews. The preliminary results will be reviewed
and modified by the OMERACT-Adherence steering
committee. Conceptual links amongst themes and
subthemes will be identified to develop an analytical
thematic schema.
Phase 3: focus groups with modified nominal group
technique with patients and caregivers
Patients and their caregivers will be asked to identify
outcome domains they regard as important and rele-
vant to measure in trials to support medication ad-
herence, and to discuss the reasons for their choices.
A modified nominal group technique will be used to
generate a prioritised set of ideas in a group system-
atically and to encourage the participation of each
member [35, 36]. The outcome domains from phases
1 and 2 will be incorporated for discussion and rank-
ing in nominal groups. Additional outcome domains
will also be identified in this phase. This study uses
both quantitative and qualitative data and has been
used successfully in the development of other OMER-
ACT core domain sets [37, 38].
Participants and recruitment
At least 12 focus groups (with a minimum of five
participants per group) will be convened. Adults aged
18 years and over with gout, osteoporosis or RA and
their caregivers will be invited to participate. The
recruitment sites and purposive sampling technique
are outlined in phase 2. In addition, focus groups will
take place in the Netherlands (through Sint
Maartenskliniek). Participants who participate in focus
groups will be different to those in individual inter-
views. The groups will be convened until data satur-
ation. The focus groups will be convened by
condition at each site. To achieve adequate partici-
pant enrolment at each site, additional recruiting cli-
nicians will be contacted if needed. Written informed
consent will be obtained from all participants.
Data collection
The focus groups will be up to 2 h in duration. An
experienced facilitator with training in the nominal
group technique and who is not involved in any pa-
tient’s care will moderate the groups to encourage
open discussion. The questions will be described in
an interview guide and discussed among the steering
committee [31]. All focus groups will be audio-taped
and transcribed verbatim. De-identified transcripts
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will be available for participants to review and revise.
A note-taker will record notes on the interaction
among the participants. The preliminary content for
the focus group run sheet is provided (Appendix 3).
Data analysis
Quantitative analysis An importance score will be
calculated for each outcome domain, based on the
rankings attributed in the focus groups, to give an
overall ranking of all outcome domains identified.
The distribution of the ranking for each outcome do-
main is calculated from the probability of each rank
for each outcome domain. The probability has two
components: (1) the importance given to the outcome
domain by the ranking and (2) the consistency of be-
ing nominated by the participants. Higher scores
identify outcome domains that are more valued by
the participants. These probabilities will be used to
compute the weighted sum of the inverted ranking
(1/i) to obtain the importance score (IS):
IS ¼
Xno of outcomes
i¼1
P Oj in rank j
  1
i
:
The importance scores will also be calculated separ-
ately for each condition, as well as for patients and care-
givers and compared using a t-test with a statistical
significance level of p < 0.05. Participants who have not
ranked at least ten outcome domains will be excluded
from this analysis. The analysis will be conducted using
statistical software Stata/SE (StataCorp. College Station,
TX) and R (R Foundation for Statistical Computing,
Vienna, Austria).
Qualitative analysis Transcripts will be imported into
HyperRESEARCH (ResearchWare Inc, http://www.re-
searchware.com, software for qualitative data analysis.
Using a thematic analysis, the transcripts will be coded
line by line by an investigator experienced in qualitative
research to identify concepts. Similar concepts will be
grouped into themes that reflect the reasons for identify-
ing and ranking the outcome domains. These themes
will be discussed by the OMERACT-Adherence steering
committee.
Phase 4: modified Delphi consensus survey
An international online OMERACT-Adherence survey
will incorporate all domains identified in phases 1–3 and
generate a consensus on up to seven core domains, as
well as other domains that may fit under the optional or
research domains. Delphi surveys have been used to gain
consensus on core domain sets in a range of health con-
ditions [39–42]. The online survey will involve three
rounds completed by participants with knowledge,
experience or expertise on the topic.
Participants and recruitment
Although Delphi surveys used to develop core domain
sets for trials in OMERACT have involved up to 250
participants [41–43], there is no agreement on the sam-
ple size required for a Delphi survey [44, 45]. To achieve
a minimum sample size of 200 respondents at the end of
the Delphi survey, by assuming 20% attrition for each
round, the initial target sample size will be 390. Par-
ticipant retention in Delphi rounds will be encour-
aged with at least two reminder emails. This will
include patients and caregivers (minimum n = 200);
rheumatologists (minimum n = 63); pharmacists,
nurses, allied health professionals and general practi-
tioners (minimum n = 63); outcomes researchers, ad-
herence researchers, clinical trialists, representatives
from the pharmaceutical industry and policymakers
(minimum n = 63).
To achieve adequate participant enrolment, partici-
pants will be identified from the networks of the
OMERACT-Adherence Group. Following this, a
snowball sampling technique will be utilised for re-
cruitment, whereby key informants will be identified
for recruitment by existing participants to ensure that
a broad range of participant characteristics (including
countries and health-care systems) and experiences
are captured.
Data collection
Generating the list of outcome domains The modi-
fied Delphi survey will include outcome domains
identified in phases 1 to 3. The survey will include a
plain language definition of each listed outcome do-
main. The survey will be reviewed by the
OMERACT-Adherence Group, and piloted with at
least three patients, three clinicians and three other
relevant stakeholders.
Survey administration The surveys will be completed
online using the survey platform Qualtrics (Qualtrics
Provo, UT). Each participant will be given a unique
identifier so that their responses from each round of the
survey can be linked anonymously. A minimum of three
reminders will be sent to participants during the Delphi
rounds, with the aim of achieving a response rate of at
least 70% across all three rounds of those who have
agreed to participate.
Delphi round 1 Participants will rate each outcome
domain using a nine-point Likert scale. Ratings 1 to
3 are not important, 4 to 6 important but not a
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priority, and 7 to 9 very important and a priority.
Unsure will also be an option. Responses will be
mandatory and participants will be encouraged to
use the full range of scores. The sequence of out-
come domains will be randomised to minimise or-
dering bias. Participants can provide comments for
each outcome domain in a free-text box and suggest
new outcome domains. All new outcome domains
that are suggested will be reviewed by the steering
committee and discussed for inclusion in round 2.
Any outcome domain where ≥70% of either patients
and caregivers or other stakeholders have rated the
outcome domain as very important and a research
priority (scores 7–9) will be retained in round 2 and
reported back to participants. All items where ≥70%
of the participants voted the item as not important
(1–3) will be excluded from the Delphi list. All the
remaining items and new items will be sent back for
re-scoring in round 2.
Delphi round 2 Participants will be presented with a
graph showing the distribution of scores for all retained
domains for (1) patients and caregivers, (2) other stake-
holders and (3) all participants. Comments from round
1 by all other participants will also be provided. The
participant’s own response from round 1 will be
highlighted. Participants will use the same Likert scale
for re-scoring. Participants can provide comments for
each outcome domain in a free-text box.
Any outcome domain where ≥70% of either patients
and caregivers or other stakeholders have rated the
outcome domain as very important and a research
priority (scores 7–9) will be retained in round 3 and
reported back to participants. All items where ≥70%
of the participants voted the item as not important
(1–3) will be excluded from the Delphi list. All the
remaining items will be sent back for re-scoring in
round 3.
Delphi round 3 Participants will view the distribution
of scores and comments for each domain from round 2.
Participants will see their own scores from round 2
highlighted and re-score outcome domains. After the
rating questions, participants will be asked to complete a
Best–worst scale survey [46]. In the best-worse survey,
the group will be presented with up to six lists that will
contain a subset of six of the outcome domains
remaining in round 3. Participants will be asked to
choose the most important and least important outcome
domains from each list. The Best–worst scaling survey
will quantify the relative importance of each of the
round 2 outcome domains.
Data analysis
The mean, median and proportion of the ratings for
each outcome domain from all three rounds will be
calculated. The scores will be calculated separately
for patients/caregivers and other stakeholders. A
Wilcoxon sign rank test or t-test will be used to
compare the mean difference in rating scores be-
tween both stakeholder groups, with a significance
value of p < 0.05. The Best–worst scale survey will
be used to calculate the relative importance score
for each of the round 2 outcome domains. Multi-
nomial logistic regression models will be used to cal-
culate a relative importance score for each outcome
domain normalised to the range 0 (least important)
to 10 (most important). Importance scores will be
calculated separately for patients, caregivers and
other stakeholders. The influence of demographic
factors, such as age, gender and condition, will be
investigated. Participants who have not completed all
three Delphi rounds will be excluded from the
analysis.
Based on previous Delphi surveys used in outcomes
research, a preliminary core domain set will be based on
the outcome domains for which ≥70% of both patients/
caregivers and other stakeholders have rated it as critic-
ally important (rating 7–9) [43]. For feasibility, up to
seven critically important outcome domains (based on
the means, medians and proportions of ratings and im-
portance score) will be identified as the preliminary core
domain set.
Phase 5: consensus workshop
A consensus workshop will review the results from
phases 1 to 4 and discuss the potential core domain
set. Strategies to develop outcome measures will also
be discussed. The target will be at least 60 partici-
pants, with a minimum of 20 patients and caregivers.
To achieve adequate participant enrolment, the
stakeholder workshop is anticipated to occur during
the 2020 OMERACT meeting. Invitations will be
extended to health professionals (rheumatologists,
pharmacists, nurses and other allied health profes-
sionals), researchers, policymakers and pharmaceut-
ical industry representatives with expertise in
medication adherence in rheumatology. To facilitate
implementation, invitees will include health
professionals who have key roles in specialty profes-
sional organisations, guidelines, registries, journals,
regulatory agencies and funding organisations. All
parts of the workshop will be audio-recorded and
transcribed.
Participants will be sent a copy of the results from
phases 1 to 4 prior to the workshop and asked to
consider the results to date, so that they are prepared
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to give informed and considered feedback. The pre-
liminary agenda for the consensus workshop is pre-
sented below.
Part 1: introduction
The aims, method and the results from OMERACT-
Adherence phases 1 to 4, including the preliminary
core domain set, proposed consensus definition and
strategies to develop outcome measurements, will be
presented by the chair of the OMERACT-Adherence
Group.
Part 2: breakout groups
Participants will be assigned to breakout groups with
approximately 12 participants per group (each with a
facilitator and co-facilitator chosen from the
OMERACT-Adherence Group). The groups will con-
tain a mixture of stakeholders, including a minimum
of two patients or caregivers, to promote the ex-
change of different perspectives. A briefing session,
including a detailed run sheet with the question
guide, will be provided to train facilitators. The facili-
tators will moderate the group discussion and take
notes to report back to the larger group, focusing on
the candidate core domains and strategies to develop
outcome measures.
Part 3: plenary discussion
The group will reconvene after the breakout group
session. Each group will report back the results of their
discussion to the wider group. Participants will be
encouraged to provide feedback on the issues raised by
other groups. The workshop chair will moderate the
forum and summarise key points.
Finalisation of the core domain set Final consensus
voting will include voting on each proposed do-
main. Changes to domains (e.g. wording or defin-
ition) will be permitted during phase 5. All
domains voted for by ≥70% of participants will be
included in the core domain set. In addition, at-
tendees will vote on whether appropriate steps out-
lined in phases 1–4 were followed to obtain the
core domain set and agreement on a proposed
research agenda for core outcome measurement de-
velopment. Following the workshop, all transcripts
will be entered into the software HyperRESEARCH
(ResearchWare Inc. http://www.researchware.com,
version 3.7.5). The data will be coded and analysed
to identify participant perspectives on the potential
core domain set, and suggestions and challenges
for implementation. The key findings will be
reviewed by the OMERACT-Adherence steering
committee prior to submitting a finalised workshop
report. Phases 1 to 5 of the OMERACT-Adherence
process, including the workshop report on the core
domain set, will be published in peer-reviewed
journals.
Discussion
OMERACT-Adherence will use a validated and system-
atic approach to develop a consensus-based core domain
set that OMERACT will recommend is reported in all
clinical trials of interventions aimed to improve medica-
tion adherence in paediatric and adult rheumatic condi-
tions. The OMERACT-Adherence core domain set may
be considered for other contexts including other special-
ties, and other types of studies such as observational
studies in which medication adherence is a key
requirement to ensure the optimal uptake of new medi-
cations. Once the OMERACT-Adherence core domain
set has been ratified by OMERACT attendees, core out-
come measurements for each of the core domains will
be identified or developed as needed using the OMER-
ACT filter to ensure that measures are truthful, discrim-
inative and feasible [47]. Guidelines for selecting
outcome measurements for core domains that have been
developed by the Core Outcome Measures in Effective-
ness Trials (COMET) and Consensus-based Standards
for the Selection of Health Measurement Instruments
(COSMIN) initiatives will also be used to guide this
process [23, 48].
In addition to publications and research presentations,
to facilitate the dissemination and uptake of the
OMERACT-Adherence core domains set into clinical
trials, national and international stakeholders will be
consulted throughout the study phases and at an imple-
mentation workshop at the completion of the study. Ul-
timately, the standardised use of a consensus-based set
of high-priority outcome domains will enable all stake-
holders to make decisions about strategies to improve
medication adherence.
Study status
Data collection and recruitment commenced for
phases 1, 2 and 3 in October 2017. A time schedule
has been adapted from the SPIRIT figure and is pro-
vided (Appendix 1). The OMERACT-Adherence five-
phase study was registered on the COMET database
on 27 November 2017 (http://www.comet-initiati-
ve.org/studies/details/1068). Any important amend-
ments to the protocol will be discussed amongst the
OMERACT-Adherence steering committee and sub-
mitted to the COMET database. The date of
submission for this protocol (version 1) is 29
November 2017.
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Appendix 1
Appendix 2
Preliminary interview guide for interviews with patients
and caregivers
1. Welcome and introduction: Aspects of treatment
that are important and challenging.
2. Current outcomes: Presentation and discussion of
outcome domains currently reported in
interventions to support patients with medication
adherence (as identified in phase 1).
3. Perspectives on outcomes: Outcome domains the
participants believe are important and relevant for
trials and the reasons why.
4. Outcome implementation: Ideas on how a core
domain set can be disseminated to the broader
group of stakeholders
Table 1 Definitions and examples of intervention functions and sources of behaviour
Intervention functions Definition Examples
Education Increasing understanding or knowledge Group patient education meetings
Persuasion Using communication to stimulate action or
induce positive or negative feelings
Using motivational interviewing to encourage
medication adherence
Incentivisation Creating an expectation of reward Payment to complete computer-based interactive
adherence programme
Coercion Creating an expectation of punishment or cost Punishment system for a child who does not
take their medications
Training Teaching skills Self-management training
Restriction Using rules to decrease the opportunity to
engage in the target behaviour
Restricting biologic prescriptions to those with
adequate adherence
Environmental
restructuring
Changing the social or physical context On-screen prompts to remind rheumatologist to
address medication adherence with patients
Modelling Providing an example for people to imitate or aspire to Peer educators motivating other patients
Enablement Increasing means or reducing barriers to increase
capability or opportunity (excluding education and
training or environmental restructuring)
Alarm device to remind patients to take medications
Controlled-release medications to reduce number
or frequency of medications
Sources of behaviour
Capability The individual’s psychological or physical capacity to
engage in the behaviour
Psychological capability (e.g. medication knowledge)
Physical capability (e.g. medication-taking skill)
Opportunity Factors that lie outside the individual that prompt a
behaviour or make it possible
Physical opportunity (e.g. cost of medication)
Social opportunity (e.g. societal acceptance of
medication taking)
Motivation All the brain processes that energise and direct behaviour Reflective motivation (e.g. analytical decision-making)
Automatic motivation (e.g. immediate emotional
response to medication taking)
Table 2 Schedule of study phases
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Appendix 3
Preliminary run sheet for focus groups with patients
and caregivers
1. Welcome and introduction (10 min): The facilitator
will explain the aims of the study, define what
outcome domains are in the context of clinical trials,
describe the scope of interventions to support
medication adherence (Fig. 1) and ask participants
to introduce themselves (including their diagnosis
and medications).
2. Focus group discussion (40 min): Participants will be
asked to discuss their experiences and motivation of
taking medications for their rheumatic condition,
including perceived benefits, harms and
complications related to their treatment.
3. Nominal group technique (70 min): Each participant
will be asked to suggest one to two domains they
consider are most important to include in trials of
interventions to support medication adherence. The
facilitator will ask participants in turn to read out
their suggestions, which will be recorded for all
participants to see on a whiteboard or flip chart.
Once the group has created their list of outcome
domains, the facilitator will add outcome domains
identified from the systematic review, patient and
caregiver interviews, and previous nominal groups.
The list of outcome domains will be discussed to
ensure that all members understand the meaning of
the outcome domains. Participants will then
individually rank all the outcome domains in the
order of perceived importance, from 1 (most
important) to X (least important). If participants
have difficulty ranking all the outcome domains,
they will be asked to rank their top ten domains.
The facilitator will ask participants to read out
their top three choices and will note this for all
to see and discuss.
Similarities and differences in ranking will be discussed
among the participating groups. The outcome domains
from each group will be reviewed and discussed among
the OMERACT-Adherence steering committee.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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